Clinical Trial Update: A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas [Phase 2]

View source ↗

Summary

Phase 2 pilot trial evaluating a tumor-specific peptide vaccine with IL-2, with or without autologous T cell transplantation, in recurrent pediatric sarcomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Rhabdomyosarcoma

Drugs mentioned

• IL-2 (Interleukin-2)
• autologous T cell transplantation
• tumor-specific peptide vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ewing's Sarcoma, Rhabdomyosarcoma | Phase 2 | Status: COMPLETED